Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of oral WJB001 in patients with advanced malignant tumors
CTR20230480Phase 2Active
- Sponsor
- Micro Biotech
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WJB001 in Nonhematologic neoplasms, Serous endometrial adenocarcinoma, High-Grade Serous Ovarian Cancer (HGSOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Micro Biotech. Started May 2023; status: active.
02
Drugs
WJB001
03
Conditions
Nonhematologic neoplasmsSerous endometrial adenocarcinomaHigh-Grade Serous Ovarian Cancer (HGSOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20230480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230480.